Elsevier obtains cancer drug compendia
Executive Summary
Scientific publisher announces definitive agreement to purchase Tampa, Fla.-based Gold Standard, Inc. a provider of drug and clinical information at the point of care. Gold Standard CEO Russ Thomas will continue to lead the organization as part of Elsevier, according to an April 19 release by both firms. With the purchase, Elsevier gains Gold Standard's eMPOWERx electronic prescribing tool and off-label oncology drug compendia currently in development. The deal comes as Medicare considers approving additional compendia for local carriers to use when making off-label coverage decisions [Editor's note: "The Pink Sheet" is published by Elsevier subsidiary F-D-C Reports]...
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: